JP2020111586A5 - - Google Patents

Download PDF

Info

Publication number
JP2020111586A5
JP2020111586A5 JP2020042730A JP2020042730A JP2020111586A5 JP 2020111586 A5 JP2020111586 A5 JP 2020111586A5 JP 2020042730 A JP2020042730 A JP 2020042730A JP 2020042730 A JP2020042730 A JP 2020042730A JP 2020111586 A5 JP2020111586 A5 JP 2020111586A5
Authority
JP
Japan
Prior art keywords
composition according
composition
solvate
salt
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020042730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020111586A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020111586A publication Critical patent/JP2020111586A/ja
Publication of JP2020111586A5 publication Critical patent/JP2020111586A5/ja
Pending legal-status Critical Current

Links

JP2020042730A 2015-02-10 2020-03-12 線維症の治療用のセニクリビロック Pending JP2020111586A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562114304P 2015-02-10 2015-02-10
US62/114,304 2015-02-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017560462A Division JP6676660B2 (ja) 2015-02-10 2015-09-22 線維症の治療用のセニクリビロック

Publications (2)

Publication Number Publication Date
JP2020111586A JP2020111586A (ja) 2020-07-27
JP2020111586A5 true JP2020111586A5 (https=) 2020-12-17

Family

ID=56614560

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017560462A Expired - Fee Related JP6676660B2 (ja) 2015-02-10 2015-09-22 線維症の治療用のセニクリビロック
JP2020042730A Pending JP2020111586A (ja) 2015-02-10 2020-03-12 線維症の治療用のセニクリビロック

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017560462A Expired - Fee Related JP6676660B2 (ja) 2015-02-10 2015-09-22 線維症の治療用のセニクリビロック

Country Status (15)

Country Link
US (3) US20180110754A1 (https=)
EP (1) EP3256124B1 (https=)
JP (2) JP6676660B2 (https=)
KR (1) KR20170113596A (https=)
CN (1) CN107405403B (https=)
AU (1) AU2015382376B2 (https=)
BR (1) BR112017016388A2 (https=)
CA (1) CA2975445A1 (https=)
ES (1) ES2864767T3 (https=)
HK (1) HK1247558A1 (https=)
IL (1) IL253617A0 (https=)
MX (1) MX2017010277A (https=)
RU (1) RU2722641C2 (https=)
SG (1) SG11201706028RA (https=)
WO (1) WO2016130179A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206702B1 (en) 2001-08-08 2011-12-28 Tobira Therapeutics, Inc. Bicyclic compound, production and use thereof
BR112017013130A2 (pt) 2014-12-23 2017-12-26 Tobira Therapeutics Inc processo de fabricação de cenicriviroc e análogos relacionados
BR112018076449A2 (pt) 2016-06-21 2019-04-09 Tobira Therapeutics, Inc. cenicriviroc purificado e intermediários purificados para fazer cenicriviroc
WO2022235440A1 (en) * 2021-04-21 2022-11-10 The United States Government As Represented By The Department Of Veterans Affairs Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2
CN116270633A (zh) * 2023-03-03 2023-06-23 神经肌肉骨骼再生医学中心有限公司 马拉韦罗在制备治疗肌肉退行性疾病的药物中的用途
CN119954974B (zh) * 2025-04-09 2025-07-22 四川康德赛医疗科技有限公司 一种工程化巨噬细胞,其制备方法及抗纤维化的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2249027A (en) * 1990-10-23 1992-04-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for hepatic failure
EP2206702B1 (en) 2001-08-08 2011-12-28 Tobira Therapeutics, Inc. Bicyclic compound, production and use thereof
JPWO2006059716A1 (ja) 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
ES2636679T3 (es) * 2011-06-27 2017-10-06 Université Pierre Et Marie Curie (Paris 6) Péptidos antagonistas de CCR2
WO2014136807A1 (ja) * 2013-03-05 2014-09-12 国立大学法人 岡山大学 細胞死抑制剤及び新規化合物
SG10201708595YA (en) * 2013-05-15 2017-11-29 Tobira Therapeutics Inc Cenicriviroc compositions and methods of making and using the same
KR101669124B1 (ko) * 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물

Similar Documents

Publication Publication Date Title
JP2020111586A5 (https=)
JP2018505218A5 (https=)
JP2017105763A5 (https=)
JP2022058688A5 (https=)
JP2019501226A5 (https=)
HRP20170624T1 (hr) Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti
JP2018168191A5 (https=)
RU2017130289A (ru) Ценикривирок для лечения фиброза
BR112013032770A2 (pt) composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase
JP2018503685A5 (https=)
JP2014511374A5 (https=)
JP2011506412A5 (https=)
JP2020535225A5 (https=)
AU2014235273A2 (en) Treatment of psoriatic arthritis using apremilast
JP2024516363A5 (https=)
JP2023533464A5 (https=)
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
HRP20130007T1 (hr) Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli
ME00685B (me) Preparati za tretiranje i prevenciju arterijske tromboze i korišćenje inhibitora faktora xa samog ili u kombinaciji sa plateletnim antiagregacionim agensom
JP2016511753A5 (https=)
JP2023516951A5 (https=)
JP2015510916A5 (https=)
JP2021535175A5 (https=)
SA521422467B1 (ar) مركبات هالو-آلِّيلامين واستخدامها
HRP20241716T1 (hr) Postupci liječenja promjena u ponašanju